Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent ...

Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Merck (MRK) ended the recent trading session at $110.18, demonstrating a -1.7% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00.

The Dow Jones Industrial Average is down Thursday afternoon with shares of Merck and Intel seeing the biggest declines for the price-weighted average.

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...

Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...